Trial Profile
A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2012 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2010 Results were presented at the 105th Annual Meeting of the American Urological Association.